130 Point-of-Care INR Monitoring for Patients with Antiphospholipid Syndrome

Background: Warfarin is the preferred anticoagulant in patients with antiphospholipid syndrome (APS). Patients with APS have lupus anticoagulant antibodies, known to slow blood clotting in vitro and falsely elevate international normalized ratio (INR) values. This reaction occurs more often with reagents used in point-of-care (POC) INR meters compared to the lab. Discrepancies between POC and lab INRs in patients with APS have been identified clinically, particularly when the POC INR result is >4.